Aptevo reports frontline AML data for mipletamig, targets Phase 2 talks in early 2027Aug 14Quarterly updateAptevo Therapeutics
Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026Aug 12Quarterly updateKura Oncology, Inc.ziftomenib
Cullinan reports Q2 2026 results, outlines T cell engager trial timelinesAug 6Quarterly updateCullinan Therapeutics Inc.
Syndax reports 2Q26 revenue growth, details EGFR and menin inhibitor pipeline additionsAug 4Quarterly updaterevumenibSyndax Pharmaceuticals Inc
Cullinan Therapeutics registers Phase 1b trial of CLN-049 with azacitidine, venetoclax in AMLJul 23Trial updateazacitidineCLN-049
Sign inSign in